CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Antibody-derived chimeric antigen receptor (CAR) T cell therapy has achieved gratifying breakthrough in hematologic malignancies but has shown limited success in solid tumor immunotherapy. Monoclonal antibody, TAB004, specifically recognizes the aberrantly glycosylated tumor form of MUC1 (tMUC1) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ru, Yazdanifar, Mahboubeh, Roy, Lopamudra Das, Whilding, Lynsey M., Gavrill, Artemis, Maher, John, Mukherjee, Pinku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543840/
https://www.ncbi.nlm.nih.gov/pubmed/31178870
http://dx.doi.org/10.3389/fimmu.2019.01149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543840/
https://www.ncbi.nlm.nih.gov/pubmed/31178870
http://dx.doi.org/10.3389/fimmu.2019.01149

Ejemplares similares